Company Overview

Immunome, Inc. is a U.S.-based biotechnology company focused on the discovery and development of targeted cancer therapies and antibody-based therapeutics. The company operates primarily within the oncology and immunotherapy sectors, with a strategic emphasis on radioligand therapies (RLTs), antibody-drug conjugates (ADCs), and precision biologics designed to address difficult-to-treat cancers. Immunome’s revenue has historically been derived from research collaborations, licensing arrangements, and financing activities, while its long-term strategy centers on advancing proprietary therapeutic candidates through clinical development.

The company evolved from an antibody discovery platform business into a more oncology-focused biotechnology developer through a series of acquisitions and portfolio expansions. A major strategic shift occurred following the acquisition of Morphimmune, which strengthened Immunome’s ADC capabilities, and the acquisition of Radiopharm Theranostics’ early-stage assets and related radioligand therapy programs. Immunome’s positioning is differentiated by its integration of antibody discovery technologies with targeted therapeutic delivery systems intended to improve efficacy and reduce systemic toxicity in oncology applications.

Business Operations

Immunome’s operations are centered on the development of proprietary therapeutic candidates within its oncology pipeline. Its core business units include ADC development programs, radioligand therapy programs, and earlier-stage antibody discovery technologies. The company controls intellectual property related to antibody engineering, target discovery, and therapeutic payload delivery. Key pipeline assets include investigational therapies directed at validated cancer targets, with programs spanning preclinical and clinical development stages.

The company primarily operates in the United States but engages in collaborations and research relationships with international biotechnology and pharmaceutical entities. Immunome has expanded its technological capabilities through acquisitions and licensing agreements, including assets associated with Morphimmune and radiopharmaceutical development initiatives. Public filings indicate that the company relies on contract research organizations, manufacturing partners, and clinical trial networks to support development activities rather than maintaining large-scale commercial manufacturing infrastructure.

Strategic Position & Investments

Immunome’s strategic direction is focused on building a diversified oncology portfolio with emphasis on precision-targeted therapies. Growth initiatives include advancing its ADC pipeline into clinical trials, expanding radioligand therapy capabilities, and leveraging antibody discovery technologies to identify new oncology targets. The company has prioritized investments in next-generation cancer therapeutics that combine tumor-targeting specificity with enhanced delivery mechanisms.

A significant component of Immunome’s strategy has involved acquisitions and portfolio expansion. The acquisition of Morphimmune added proprietary ADC technology platforms and oncology assets, while subsequent investments in radiopharmaceutical programs broadened the company’s exposure to emerging cancer treatment modalities. Immunome has also emphasized translational medicine and biomarker-driven development strategies intended to improve patient selection and clinical outcomes. Public disclosures indicate ongoing investment in research and development infrastructure as the company transitions toward later-stage clinical execution.

Geographic Footprint

Immunome is headquartered in Bothell, Washington, with operational and research activities connected to facilities and partnerships across the United States. The company also maintains scientific and operational ties to Pennsylvania, reflecting its historical research presence and biotechnology network connections. Its primary market focus remains the U.S. biotechnology and pharmaceutical ecosystem, particularly in oncology drug development.

Although Immunome does not currently operate as a large multinational commercial enterprise, its clinical development activities and partnership arrangements have international dimensions through global clinical trial participation, manufacturing relationships, and scientific collaborations. The company’s therapeutic programs are intended for broader global oncology markets, including potential future commercialization opportunities across North America, Europe, and other major pharmaceutical regions.

Leadership & Governance

Immunome is led by executives with backgrounds in biotechnology, oncology drug development, finance, and pharmaceutical commercialization. The company’s governance structure reflects a strategic focus on clinical execution, capital allocation, and advancement of oncology therapeutics. Leadership communications and public filings emphasize disciplined pipeline development, targeted acquisitions, and long-term value creation through differentiated cancer therapies.

Key executives include:

• Clay B. Siegall – Executive Chairman
• Stephen T. Kelley – Chief Executive Officer
• Andrew S. Levin – Chief Financial Officer
• Kristen M. Albright – Chief People Officer
• Mark W. Frohlich, M.D. – Chief Medical Officer
• Siddhartha Kadia, M.D. – Chief Business Officer

The company’s leadership strategy has emphasized integrating acquired technologies into a unified oncology platform while advancing clinical-stage assets with potential commercial applicability. Public company filings, investor presentations, and executive statements consistently identify oncology innovation, precision targeting, and disciplined portfolio expansion as central elements of Immunome’s strategic vision.